{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Saline+%280.9%25+NaCl%29&page=2",
    "query": {
      "intervention": "Saline (0.9% NaCl)",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 3084,
    "total_pages": 309,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Saline+%280.9%25+NaCl%29&page=3&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Saline+%280.9%25+NaCl%29&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-09T19:59:15.403Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01673178",
      "title": "Multiple Dose Study Of PF-05231023 In Adult Subjects Who Have Poor Lipid Control With And Without Type 2 Diabetes Mellitus",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Diabetes Melliuts, Type 2"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "OTHER"
        },
        {
          "name": "25 mg PF-05231023",
          "type": "DRUG"
        },
        {
          "name": "50 mg PF-05231023",
          "type": "DRUG"
        },
        {
          "name": "100 mg PF-05231023",
          "type": "DRUG"
        },
        {
          "name": "150 mg PF-05231023",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "30 Years to 70 Years"
      },
      "enrollment_count": 107,
      "start_date": "2012-10",
      "completion_date": "2013-09",
      "has_results": true,
      "last_update_posted_date": "2015-02-16",
      "last_synced_at": "2026-10-09T19:59:15.403Z",
      "location_count": 17,
      "location_summary": "Anaheim, California • Chula Vista, California • Walnut Creek, California + 10 more",
      "locations": [
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Chula Vista",
          "state": "California"
        },
        {
          "city": "Walnut Creek",
          "state": "California"
        },
        {
          "city": "DeLand",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01673178"
    },
    {
      "nct_id": "NCT05458947",
      "title": "Physical Therapy Wound Care Modalities in Patients With Spinal Cord Injury (SCI)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Spinal Cord Injuries",
        "Pressure Injuries"
      ],
      "interventions": [
        {
          "name": "pulsed wound irrigation (PWI)",
          "type": "PROCEDURE"
        },
        {
          "name": "electrical stimulation (ES)",
          "type": "PROCEDURE"
        },
        {
          "name": "electrical stimulation (ES) and pulsed wound irrigation (PWI)",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "Wake Forest University Health Sciences",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2022-10-11",
      "completion_date": "2026-10",
      "has_results": false,
      "last_update_posted_date": "2026-04-08",
      "last_synced_at": "2026-10-09T19:59:15.403Z",
      "location_count": 1,
      "location_summary": "Charlotte, North Carolina",
      "locations": [
        {
          "city": "Charlotte",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05458947"
    },
    {
      "nct_id": "NCT02123615",
      "title": "ASIS for GAMMAGARD in Primary Immunodeficiency",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Primary Immunodeficiency"
      ],
      "interventions": [
        {
          "name": "Gadolinium For abdomen",
          "type": "DRUG"
        },
        {
          "name": "Gadolinium For lower back",
          "type": "DRUG"
        },
        {
          "name": "Efficacy of Gammagard subcutaneously at Week 12",
          "type": "DRUG"
        },
        {
          "name": "Efficacy of Gammagard subcutaneously at Week 24",
          "type": "DRUG"
        },
        {
          "name": "Efficacy of Gammagard subcutaneously at Week 36",
          "type": "DRUG"
        },
        {
          "name": "Efficacy of Gammagard subdermally at Week 36",
          "type": "DRUG"
        },
        {
          "name": "Efficacy of Gammagard subdermally at Week 12",
          "type": "DRUG"
        },
        {
          "name": "Efficacy of Gammagard subdermally at Week 24",
          "type": "DRUG"
        },
        {
          "name": "Adverse Reactions of Gammagard subcutaneously at Week 12",
          "type": "DRUG"
        },
        {
          "name": "Adverse Reactions of Gammagard subcutaneously at Week 24",
          "type": "DRUG"
        },
        {
          "name": "Adverse Reactions of Gammagard subcutaneously at Week 36",
          "type": "DRUG"
        },
        {
          "name": "Adverse Reactions of Gammagard subdermally at Week 12",
          "type": "DRUG"
        },
        {
          "name": "Adverse Reactions of Gammagard subdermally at Week 24",
          "type": "DRUG"
        },
        {
          "name": "Adverse Reactions of Gammagard subdermally at Week 36",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ASIS Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "21 Years to 65 Years"
      },
      "enrollment_count": 60,
      "start_date": "2016-01",
      "completion_date": "2016-06",
      "has_results": false,
      "last_update_posted_date": "2015-06-24",
      "last_synced_at": "2026-10-09T19:59:15.403Z",
      "location_count": 1,
      "location_summary": "Westminster, California",
      "locations": [
        {
          "city": "Westminster",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02123615"
    },
    {
      "nct_id": "NCT03237325",
      "title": "DOM-INNATE: Study of SGX942 for the Treatment of Oral Mucositis in Patients With Concomitant Chemoradiation Therapy for Head and Neck Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Squamous Cell Carcinoma of the Oral Cavity and Oropharynx",
        "Oral Mucositis"
      ],
      "interventions": [
        {
          "name": "SGX942",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Soligenix",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 266,
      "start_date": "2017-12-04",
      "completion_date": "2021-06-24",
      "has_results": true,
      "last_update_posted_date": "2022-11-08",
      "last_synced_at": "2026-10-09T19:59:15.403Z",
      "location_count": 32,
      "location_summary": "Tucson, Arizona • Loma Linda, California • Pomona, California + 29 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Loma Linda",
          "state": "California"
        },
        {
          "city": "Pomona",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Miami Lakes",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03237325"
    },
    {
      "nct_id": "NCT06678074",
      "title": "Pilot Study of IC14 (Atibuclimab), an Anti-CD14 Monoclonal Antibody, to Treat STEMI",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "STEMI",
        "STEMI (ST Elevation MI)",
        "STEMI - ST Elevation Myocardial Infarction (MI)",
        "Stent Implantation"
      ],
      "interventions": [
        {
          "name": "Atibuclimab (IC14), 20 mg/kg intravenously, once",
          "type": "DRUG"
        },
        {
          "name": "Placebo, 150 mL intravenously, once",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Implicit Bioscience",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 10,
      "start_date": "2025-02-06",
      "completion_date": "2026-09-01",
      "has_results": false,
      "last_update_posted_date": "2026-03-27",
      "last_synced_at": "2026-10-09T19:59:15.403Z",
      "location_count": 2,
      "location_summary": "St Louis, Missouri • Charlottesville, Virginia",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Charlottesville",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06678074"
    },
    {
      "nct_id": "NCT04633889",
      "title": "Deferoxamine for the Prevention of Cardiac Surgery-Associated Acute Kidney Injury",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Kidney Injury"
      ],
      "interventions": [
        {
          "name": "Deferoxamine",
          "type": "DRUG"
        },
        {
          "name": "Normal saline",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Brigham and Women's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 320,
      "start_date": "2021-04-13",
      "completion_date": "2026-07-01",
      "has_results": true,
      "last_update_posted_date": "2026-10-06",
      "last_synced_at": "2026-10-09T19:59:15.403Z",
      "location_count": 3,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04633889"
    },
    {
      "nct_id": "NCT07454915",
      "title": "PVX4 for the Treatment of Human Papilloma Virus (HPV)16+ Cervical Dysplasia",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cervical Intraepithelial Neoplasia Grade 2/3",
        "Human Papilloma Virus Infection Type 16"
      ],
      "interventions": [
        {
          "name": "PVX4 Combination Product",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Placebo Control",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT",
        "OTHER"
      ],
      "sponsor": "PapiVax Biotech, Inc.",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 60 Years · Female only"
      },
      "enrollment_count": 138,
      "start_date": "2026-04-01",
      "completion_date": "2028-06",
      "has_results": false,
      "last_update_posted_date": "2026-05-06",
      "last_synced_at": "2026-10-09T19:59:15.403Z",
      "location_count": 1,
      "location_summary": "The Bronx, New York",
      "locations": [
        {
          "city": "The Bronx",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07454915"
    },
    {
      "nct_id": "NCT07151417",
      "title": "Use of Corticosteroid in Intraopertive Injections in Total Knee Replacement Surgery.",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Knee Osteoarthritis",
        "Musculoskeletal Disease",
        "Surgery"
      ],
      "interventions": [
        {
          "name": "PAI",
          "type": "DRUG"
        },
        {
          "name": "PAI + steroid",
          "type": "DRUG"
        },
        {
          "name": "PAI + zilretta",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Walter Reed National Military Medical Center",
      "sponsor_class": "FED",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 240,
      "start_date": "2026-09-01",
      "completion_date": "2027-08-31",
      "has_results": false,
      "last_update_posted_date": "2026-08-19",
      "last_synced_at": "2026-10-09T19:59:15.403Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07151417"
    },
    {
      "nct_id": "NCT01230424",
      "title": "Effect of Steroid Injections in a Knee With Osteoarthritis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Osteoarthritis (OA) of the Knee"
      ],
      "interventions": [
        {
          "name": "Triamcinolone Acetonide",
          "type": "DRUG"
        },
        {
          "name": "0.9% Sodium Chloride Injection as Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Tufts Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "45 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "45 Years and older"
      },
      "enrollment_count": 140,
      "start_date": "2011-03",
      "completion_date": "2015-01",
      "has_results": true,
      "last_update_posted_date": "2017-07-31",
      "last_synced_at": "2026-10-09T19:59:15.403Z",
      "location_count": 2,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01230424"
    },
    {
      "nct_id": "NCT00600002",
      "title": "Administration as a Biological Adjuvant in Clinically-Staged, Resectable Pancreatic Adenocarcinoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Resectable Pancreatic Adenocarcinoma",
        "Pancreatic Cancer"
      ],
      "interventions": [
        {
          "name": "GM-CSF",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Edward Nelson",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2004-06",
      "completion_date": "2018-04",
      "has_results": false,
      "last_update_posted_date": "2018-06-11",
      "last_synced_at": "2026-10-09T19:59:15.403Z",
      "location_count": 1,
      "location_summary": "Orange, California",
      "locations": [
        {
          "city": "Orange",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00600002"
    }
  ]
}